Microbial Fermentation Technology Market Report Scope & Overview:

The Microbial Fermentation Technology Market size was USD 35.86 Billion in 2025 and is expected to reach USD 63.72 Billion by 2035, growing at a CAGR of 5.91% from 2026–2035.

The Microbial Fermentation Technology Market is expanding owing to an increase in the requirement for biopharmaceutical products, including antibiotics, vaccines, monoclonal antibodies, and recombinant proteins. The rising prevalence of chronic diseases and outbreaks is fueling the manufacturing of biological drugs. Growth can also be attributed to various applications in probiotics, enzymes, and biotechnology industries. Developments in fermentation process, genetic engineering, and synthetic biology are helping improve efficiency and scaling of manufacturing. Moreover, increased investments in bio manufacturing, biosimilar pipeline, and cost-effective manufacturing processes are significantly propelling market growth on a global scale.

According to the World Health Organization (WHO), infectious diseases continue to account for millions of deaths annually, including approximately 1.3 million deaths from tuberculosis (2023 estimate range), underscoring the need for large-scale antibiotic production through microbial fermentation systems. The WHO also reports over 14.9 million new cancer cases annually, driving demand for monoclonal antibodies and biologics, many of which are produced using recombinant fermentation technologies. Furthermore, the Food and Agriculture Organization (FAO) highlights that global demand for enzymes and fermentation-derived food ingredients is rising significantly due to increasing protein needs and global food security requirements.

Microbial Fermentation Technology Market Size and Forecast

• Market Size in 2026E: USD 37.99 Billion

• Market Size by 2035: USD 63.72 Billion

• CAGR: 5.91% from 2026 to 2035

• Fastest Growing Region: North America

• Largest Region: Asia Pacific

To Get more information On Microbial Fermentation Technology Market - Request Free Sample Report

Microbial Fermentation Technology Market Trends

• Microbial strain engineering advances are improving fermentation efficiency, scalability, and overall yield.

• Synthetic biology and genetic engineering are expanding the range of compounds fermentation can produce.

• Alternative protein companies using fermentation attracted roughly USD 515 million in funding during 2023.

• CRISPR-Cas gene editing integration is becoming a meaningful tool for fermentation strain development.

• Optimization of fermentation media using both modern and classical techniques is improving overall production yields.

• CMO and CDMO outsourcing is rising as pharmaceutical companies seek scalable, efficient production partners.

• Growing biofuel and renewable energy demand is expanding fermentation's role in sustainable manufacturing.

• Strategic partnerships and acquisitions are letting companies expand fermentation technology portfolios and market reach.

The U.S. Microbial Fermentation Technology Market Outlook

The U.S. Microbial Fermentation Technology Market size was USD 7.99 Billion in 2025 and is expected to reach USD 14.62 Billion by 2035, growing at a CAGR of 6.23% from 2026–2035.

The US Microbial Fermentation Technology Market is expected to witness growth owing to the high demand for biologics, vaccines, monoclonal antibodies, and recombinant proteins. The rise in the incidence of both chronic and infectious diseases is propelling the development of biomanufacturing operations. Moreover, the strong presence of CDMOs, ongoing R&D activities, and the development of fermentation technology is ensuring improved productivity.

In September 2024, Lonza completed an expansion of its microbial manufacturing facility in Visp, Switzerland. The facility added two 4,000-liter fermenters, increasing capacity for biologics production. This expansion reflects growing demand for microbially-derived biologics across the pharmaceutical industry.

According to the U.S. Food and Drug Administration (FDA), biologics account for approximately 50% of all drugs in the late-stage pipeline, with most requiring advanced fermentation or bioreactor-based production systems. This highlights the growing dependence of modern drug development on microbial and cell-based manufacturing platforms.

Microbial Fermentation Technology Market Segment Analysis

• By Application, antibiotics segment dominated the Microbial Fermentation Technology Market in 2025 with 26% share; probiotics supplements segment is the fastest growing segment.

• By End-user, bio-pharmaceutical companies segment dominated the market in 2025 with 44% share; CMOs & CDMOs segment is the fastest growing segment.

By Application, antibiotics segment dominates the microbial fermentation technology market, while probiotics supplements segment is the fastest-growing segment

The antibiotics segment dominated the Microbial Fermentation Technology Market in 2025 owing to their well-established application in the commercial production of anti-infective medicines. The ability of microbial fermentation technology to produce inexpensive and high yields of anti-bacterial drugs helps maintain the dominance of this segment. Increasing demand from end users for potent antimicrobials and requirement for uninterrupted supply chains during production have contributed significantly towards maintaining the supremacy of this market segment.

The probiotics supplements segment is the fastest growing owing to the increased awareness among consumers about the importance of gastrointestinal health, immune system strength, and preventive healthcare measures. Growing demand for foods and dietary supplements that contain living beneficial microbes is fueling the need for microbial fermentation technology to produce them. Application areas for probiotics supplements continue to expand in nutraceuticals, infant formula, and digestive supplements.

By End-user, biopharmaceutical companies segment dominates the microbial fermentation technology market, while CMOs & CDMOs segment is the fastest-growing segment

The bio-pharmaceutical companies segment dominated the market in 2025 as it involved massive fermentation processes in the production of drugs, vaccines, enzymes, and biologics. They have the most sophisticated production process and heavily invested in fermentation-based production systems to ensure purity and scalability. In addition to that, a robust pipeline for research and development, biologics production, and efficient production of drugs are key drivers behind this segment's dominance.

The CMOs & CDMOs segment is the fastest growing due to outsourcing of the fermentation process by pharmaceutical and biotechnological companies. The need to reduce manufacturing expenses and fasten the time-to-market process are key contributors to this trend. CMOs & CDMOs have specialized processes and sophisticated fermentation systems. Moreover, complexities of biologics and an increase in biosimilars and vaccines pipeline will drive the outsourcing trend.

Regional Analysis

North America Microbial Fermentation Technology Market Insights

North America is growing fastest in this market, at a CAGR of approximately 7.39%. Robust R&D investment and rising demand for biologics and specialty chemicals both drive this growth. The presence of key market players keeps fueling continued technological innovation across the region. Strong venture capital activity in synthetic biology startups is also reinforcing this growth trajectory.

The United States accounts for approximately 82.5% of North American revenue. Continuous fermentation technology innovation keeps attracting growing investment across the region. As sustainable manufacturing demand keeps rising, North America should keep outpacing the global average.

The U.S. Centers for Disease Control and Prevention (CDC) reports that seasonal influenza affects between 9–41 million people annually in the United States, while COVID-19 has caused over 1 million deaths, both of which have significantly accelerated investments in vaccine development and large-scale fermentation capacity. Furthermore, the U.S. Department of Energy (DOE) estimates that industrial biotechnology could reduce greenhouse gas emissions by up to 1 billion metric tons annually, further driving adoption of fermentation-based bio-manufacturing as a sustainable alternative to traditional chemical production processes.

Europe Microbial Fermentation Technology Market Insights

Europe represents a steady, established market supported by strong pharmaceutical manufacturing capability. Germany leads the regional market, backed by advanced industrial biotechnology research capacity. France and the UK contribute meaningful demand through their own established life sciences sectors. Growing sustainability mandates across the EU continue reinforcing demand for greener production methods.

Germany accounts for approximately 24.6% of European revenue. Growing sustainability-focused regulation across the EU keeps reinforcing demand for fermentation-based production methods. This regulatory direction should keep supporting steady European market growth.

According to the European Medicines Agency (EMA), biologics now account for over 40% of all newly approved medicines in the European Union, with most relying on microbial and cell fermentation systems for their production, underscoring the central role of fermentation technologies in modern pharmaceutical manufacturing.

Additionally, the European Centre for Disease Prevention and Control (ECDC) reports that infectious disease outbreaks continue to place a significant surveillance burden across the region, with tens of thousands of confirmed outbreaks annually, sustaining steady demand for vaccines, antibiotics, and other fermentation-derived therapeutics.

Asia Pacific Microbial Fermentation Technology Market Insights

Asia Pacific dominated the market in 2023, accounting for approximately 47% of global revenue. A strong manufacturing base and rising biopharmaceutical demand both support this regional leadership. Cost-effective production capabilities and vast raw material availability further reinforce this position. Government policies promoting food and feed industry expansion across China and India add further momentum.

According to the World Health Organization (WHO), Asia accounts for over 60% of the global infectious disease burden, significantly driving demand for vaccines, antibiotics, and other fermentation-derived therapeutics.

Additionally, India’s Department of Biotechnology (DBT) reports that the country’s biopharma sector is valued at over USD 80 billion, with rapid expansion in vaccine and biosimilar production capacity increasingly supported by microbial fermentation technologies.

China accounts for approximately 40.6% of Asia Pacific revenue. Growing biotechnology investment and rapidly expanding healthcare infrastructure both support continued regional growth. This combination of cost advantage and capacity expansion should sustain Asia Pacific's leading position.

Furthermore, China’s National Medical Products Administration (NMPA) highlights more than 200 biologics and biosimilar clinical pipelines, many of which rely heavily on fermentation-based manufacturing systems for upstream production.

Get Customized Report as per Your Business Requirement - Enquiry Now

MEA & Latin America Microbial Fermentation Technology Market Insights

The UAE leads MEA revenue at approximately 22.8%. Rising attention to food safety and quality nutrition needs both support growing regional demand. Saudi Arabia is also investing in biotechnology infrastructure to diversify its broader economy. The Middle East overall is showing a particularly strong growth trajectory tied to food security priorities. Regional governments increasingly view domestic fermentation capacity as a strategic food security asset.

According to the World Health Organization (WHO), Africa imports more than 70% of its pharmaceuticals, highlighting a significant reliance on external supply chains and creating strong incentives for developing domestic biomanufacturing capabilities.

Brazil leads Latin American revenue at approximately 43.8%. Growing food and beverage production capacity keeps driving regional fermentation technology demand. Mexico and Argentina contribute secondary demand through their own expanding agricultural and biotech sectors.

According to the Pan American Health Organization (PAHO), infectious diseases continue to represent a significant disease burden in the region, while vaccination programs now cover over 90% of children in most countries, sustaining continuous demand for vaccine production and fermentation-based manufacturing systems.

Additionally, Brazil’s Fiocruz Foundation (Oswaldo Cruz Foundation) plays a critical role in regional biomanufacturing by producing millions of vaccine doses annually using microbial fermentation systems to support national immunization programs.

Market Dynamics

Growth Drivers: Growing demand for sustainable biotechnological products driving market growth

Demand for biotechnology products is another critical factor behind the growth of this market. In recent years, fermentation has emerged as an effective technique for the creation of biofuels, food additives, and pharmaceuticals. Compared to traditional chemical methods, the fermentation process is both sustainable and more efficient. The technique used in microbial fermentation is versatile enough to enable the manufacture of various types of bioproducts in scalable manner. Advancements in fermentation techniques continue to bolster the importance of this technology in biotechnology. Companies' sustainability goals are encouraging them to employ fermentation processes over chemicals.

Growing consumer interest in eco-friendly, plant-based products is yet another major driver behind the adoption of fermentation technology. Fermentation presents an innovative method to efficiently obtain natural food ingredients without harming the environment. This trend is most prevalent in the rapidly expanding field of plant-based food and beverages. This is because the fermentation process can facilitate the creation of complex molecules, which are needed for the rising popularity of GMO-free food. With growing consumer preference for natural foods, companies are allocating more shelf space to natural ingredient brands.

Restraints: Process complexity limiting scalability and cost efficiency

The natural complexity of fermentation processes serves as a significant limitation on market expansion. Temperature, pH, and oxygen concentration control is needed to ensure production efficiency. Such control becomes quite tedious and costly when done on a commercial level. QA specialists need to constantly monitor several parameters throughout each batch. Slight variations may lead to expensive correction or scrapping of an entire batch in regulated environments.

Minor fluctuations in production parameters even during large-scale production may significantly impact overall production efficiency. The added expenses involved in monitoring and controlling production processes complicate matters even further. This complexity constitutes a genuine limitation when compared to cheaper alternatives available to the manufacturing industry. For smaller companies, it becomes difficult to make a case for such high expenses. Specialized personnel is often lacking in the field as well.

Opportunities: Synthetic biology and genetic engineering advances expanding fermentation's commercial potential

New innovations in synthetic biology and genetic engineering provide notable opportunities for growth in the industry. This should contribute positively to the complexity level of chemical molecules produced by fermentation technology. The optimization of production processes should make significant contributions towards cutting costs involved in manufacturing. Incorporation of CRISPR-Cas gene editing is a notable development in strain engineering.

The applications of biopharmaceuticals such as vaccines and biologics present one key opportunity for growth. The fermentation process of microbes will continue to be essential in the creation of these pharmaceutical products. Early investments into the development of the next generation strain engineering should yield a considerable competitive edge for companies. Collaborations between startups and biotech manufacturers will serve to further drive the innovation pipeline in this sector. Given the growing demand for biologics worldwide, the biopharmaceuticals opportunity should remain robust in the future.

Recent Developments:

• 2024: Danone launched a biotech accelerator with a €16 million investment to advance precision fermentation for bio-based ingredients.

• 2024: Lonza completed an expansion of its microbial manufacturing facility in Visp, Switzerland, adding two 4,000-liter fermenters for biologics production.

• 2023: FrieslandCampina and Triplebar Bio expanded their collaboration to scale cell-based proteins through precision fermentation for alternative protein solutions.

Microbial Fermentation Technology Market Key Players are:

• Danaher Corporation

• Cytiva

• Sartorius AG

• Merck KGaA

• Thermo Fisher Scientific Inc.

• Lonza Group AG

• WuXi Biologics

• Samsung Biologics

• FUJIFILM Diosynth Biotechnologies

• Catalent Inc.

• Boehringer Ingelheim

• Ajinomoto Co., Inc.

• Novonesis

• Evonik Industries AG

• BASF SE

• DSM-Firmenich

• Eppendorf SE

• Pall Corporation

• Getinge AB

• Sino Biological Inc.

Microbial Fermentation Technology Market Report Scope: